| Item Type | Name |
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
|
Academic Article
|
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation.
|
|
Academic Article
|
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors.
|
|
Academic Article
|
Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
|
|
Academic Article
|
Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
|
|
Academic Article
|
Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations.
|
|
Academic Article
|
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
|
|
Academic Article
|
An oxaliplatin + 5-fluorouracil bolus + folinic acid (BFOL) regimen as first-line treatment in metastatic colorectal cancer patients.
|
|
Academic Article
|
Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.
|
|
Academic Article
|
Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey.
|
|
Academic Article
|
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
|
|
Academic Article
|
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
|
|
Academic Article
|
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
|
|
Academic Article
|
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.
|
|
Academic Article
|
Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
|
|
Academic Article
|
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
|
|
Academic Article
|
Role of cetuximab in the treatment of patients with NSCLC: are we throwing out the baby with the bath water?
|
|
Academic Article
|
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
|
|
Academic Article
|
Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.
|
|
Academic Article
|
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
|
|
Academic Article
|
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.
|
|
Academic Article
|
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
|
|
Academic Article
|
[Locoregional therapy in hepatic metastases of colorectal cancer].
|
|
Academic Article
|
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
|
|
Academic Article
|
Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?
|
|
Academic Article
|
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.
|
|
Academic Article
|
Across the universe of K-RAS mutations in non-small-cell-lung cancer.
|
|
Academic Article
|
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
|
|
Academic Article
|
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.
|
|
Academic Article
|
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.
|
|
Academic Article
|
Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study.
|
|
Academic Article
|
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma.
|
|
Academic Article
|
A lesson from vorinostat in pleural mesothelioma.
|
|
Academic Article
|
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
|
|
Academic Article
|
Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers.
|
|
Academic Article
|
Afatinib for lung cancer: let there be light?
|
|
Academic Article
|
Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet.
|
|
Academic Article
|
New strategies in colon cancer adjuvant therapy.
|
|
Academic Article
|
Bevacizumab for non-small-cell lung cancer.
|
|
Academic Article
|
Cetuximab for metastatic colorectal cancer.
|
|
Academic Article
|
Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?
|
|
Academic Article
|
Treatment of lung large cell neuroendocrine carcinoma.
|
|
Academic Article
|
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
|
|
Academic Article
|
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
|
|
Academic Article
|
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.
|
|
Academic Article
|
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407.
|
|
Academic Article
|
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
|
|
Academic Article
|
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
|
|
Academic Article
|
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial.
|
|
Academic Article
|
Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.
|
|
Academic Article
|
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
|
|
Academic Article
|
Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer.
|
|
Academic Article
|
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
|
|
Academic Article
|
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.
|
|
Academic Article
|
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide.
|
|
Academic Article
|
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.
|